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cancer,	 in	which	 a	 central	 resection	with	 high	 ligation	 of	 the	 ileocolic	 axis	 is	mandatory	 for	 complete	 removal	 of	
tumor-draining	 lymphovascular	 tissue.	 Conversely,	 CD	 typically	 needs	 less	 radical	 resection	 of	 lymphovascular	





(n=153	 (78%)	 with	 cancer	 and	 n=42	 (22%)	 with	 CD)	 were	 included.	 We	 collected	 demographic	 and	 surgical	
information,	 functional	 outcomes	 (postoperative	 pain	 level,	 opioid	 use,	 time	 from	 surgery	 to	 return	 to	 flatus	 and	
stool,	 postoperative	 oral	 intake	 of	 fluids,	 postoperative	 weight	 change	 and	 postoperative	 mobilization),	




significantly	 more	 pain	 at	 POD	 0-3,	 and	 significant	 differences	 were	 observed	 in	 intraoperative	 EDA	 use	 and	
postoperative	opioid	use	within	48	hours.	Return	of	flatus	and	stool	was	similar	in	both	groups	and	no	difference	was	
seen	 in	surgical	outcome.	Oncological	patients	gained	significantly	more	weight	and	had	a	 larger	 lymph	node	yield	
than	the	CD	group.		
	
Conclusion.	 This	 study	 did	 not	 reveal	 differences	 in	 functional	 and	 surgical	 outcome	 in	 CD	 and	 cancer	 patients	











tract1.	 Despite	 being	 a	 non-curative	 disease,	 more	 than	 half	 of	 patients	 need	 surgical	 treatment2	 for	 medically	
refractory	 inflammation	 leading	 to	 acute	 (i.e.	 perforation)	 or	 chronic	 (i.e.	 stricture)	 complications.	With	 58%,	 the	
ileocecal	 segment	 is	 the	most	 prevalent	 primary	 location3	 of	 the	 disease	 and	may	 require	 ileocecal	 resection	 for	
disease	control2,4.	 Formal	 right	 colectomy	 is	 the	 standard	approach	 to	 right-sided	colon	cancer,	 in	which	a	central	
resection	 with	 high	 ligation	 of	 the	 ileocolic	 axis	 is	 mandatory	 for	 complete	 removal	 of	 tumor-draining	
lymphovascular	 tissue.	 Conversely,	 CD	 typically	 needs	 less	 radical	 resection	 of	 lymphovascular	 structures	 and	 is	
mainly	guided	by	the	extent	of	the	inflammatory	process.			
Assuming	 that	 the	Abbreviated	 Injury	 Scale	 (AIS)	 for	mesenteric	 injury	 in	 traumatology	 increases	 the	 risk	of	 small	
bowel	obstruction5,	central	resection	of	the	ileocolic	pedicle	and	its	neurovascular	structures	may	have	an	impact	on	
functional	recovery	including	postoperative	ileus	(POI),	which	occurs	in	up	to	24%	after	right	colectomy6.		
The	aim	of	 this	 study	was	 to	 compare	 functional	 recovery	and	 surgical	outcomes	of	patients	undergoing	 ileocecal	






the	 Centre	 Hospitalier	 Universitaire	 Vaudois,	 a	 tertiary	 academic	 institution.	 All	 consecutive	 patients	 undergoing	
right	 colectomy	 or	 ileocecal	 resection	 for	 either	 primary,	 histology-proven	 stage	 I-III	 adenocarcinoma	 or	 Crohn’s	
disease	with	an	established	preoperative	diagnosis	between	July	2011	and	November	2017	were	included.		
The	study	was	conducted	in	accordance	with	the	STROBE	criteria	(https://strobe-statement.org).	





information	 included	 surgical	 approach	 (either	 open	 or	 minimally	 invasive,	 including	 pre-emptive	 or	 reactive	
conversion	to	laparotomy),	elective	or	emergency	(within	72	hours	of	unplanned	admission)	indication,	length	of	the	
operation	 (from	 anesthesia	 induction	 until	 skin	 closure)	 and	 length	 of	 the	 incision	 (<	 10cm	 vs.	 >	 10cm).	 	 For	 CD	
patient	 a	 bowel-close	 resection	 was	 performed.	 None	 of	 the	 cancer	 patient	 underwent	 a	 D3-lymphadenectomy,	
however	complete	mesocolic	excision	preserving	the	mesocolic	plane	and	central	ligation	of	the	ileocolic	vessels	at	











infection	 and	 pneumonia),	 respiratory	 and	 cardiovascular	 complications	 (arrhythmias,	 deep	 venous	 thrombosis,	
pulmonary	 embolism),	 urinary	 retention	 (need	 for	 in	 and	 out	 catheterization),	 anastomotic	 leakage	 (clinically	 or	
radiologically	 confirmed),	 postoperative	 length	 of	 stay	 (surgery	 to	 discharge),	 readmission	 (to	 either	 index	 or	







AZA,	 Methotrexate	 -	 MTX)	 and	 biologic	 molecules	 (Adalimumab	 -	 ADA,	 Certolizumab	 -	 CTZ,	 Infliximab	 -	 IFX,	
Vedolizumab	 –	 VED	 and	 Ustekinumab	 –	 UST),	 which	 were	 stopped	 at	 minimal	 half-life	 time	 of	 drug	 except	 for	





Statistical	 analyses	 were	 performed	 with	 the	 Statistical	 Software	 for	 the	 Social	 Sciences	 (SPSS	 22).	 Descriptive	
statistics	were	reported	as	 frequency	and	percentages	and	continuous	variables	were	reported	as	mean	(standard	









































Surgery	 is	 not	 a	 curative	 treatment	 for	 CD.	 Endoscopic	 recurrence	 occurs	 in	 30%9,	10,	11,	12	 at	 1	 year	 and	 85%	 at	 3	
years13	after	surgery,	while	clinical	recurrence	at	one	year	occurs	in	8-20%10,	11,	13.	Furthermore,	surgical	recurrence	
occurs	 in	30%	of	patients	at	10	years14,	15.	High	visceral	 fat	area	and	high	mesenteric	 fat	 index	are	associated	with	
postoperative	 recurrence	at	6	months16.	 In	2018,	Coffey	et	al17	evaluated	 the	 rate	of	 surgical	 recurrence	between	





potential	 immunologic	 reactions.	 The	 authors	 also	 explained	 the	 beneficial	 effect	 of	 mesenteric	 resection	 by	
assuming	 that	 it	 reduces	 the	 local	 recruitment	 of	 fibrocytes.	 The	 percentage	 of	 fibrocytes	 correlated	 with	 the	
mesenteric	disease	severity,	which	in	turn	correlated	to	the	CD	activity	index	(CDAI)	and	the	mucosal	disease	activity	




protection	 of	 fat	 wrapping18,	 19.	 According	 to	 their	 studies,	 radical	 mesenteric	 resection	 could	 therefore	 lead	 to	
poorer	 clinical	 outcomes.	 Furthermore,	 resection	 of	 the	 mesentery	 is	 associated	 with	 a	 non-negligible	 risk	 of	
bleeding,	which	can	cause	major	peri-	and	postoperative	complications20.	In	the	present	study,	mesenteric	resection	
did	not	 lead	 to	 increased	overall	 and	 specific	 postoperative	 complication	 rates.	Hence,	 our	 results	may	 support	 a	
more	extended	surgical	approach	in	CD.	However,	whether	the	mesentery	has	an	immunological	protection	or	not	in	
ileocecal	CD	needs	yet	to	be	determined	by	further	studies.	
Mascarenhas	 et	 al21	 analyzed	 short-term	 outcomes	 after	 ileocolic	 resection	 and	 right	 hemicolectomies	 for	 CD	
patients	 compared	 with	 a	 non-Crohn’s	 comparative	 group	 and	 showed	 no	 differences	 in	 postoperative	 needs	 of	
surgical	 re-intervention	and	postoperative	 ileus.	They	concluded	 that	 the	underlying	pathology	does	not	 influence	
functional	recovery	and	surgical	outcomes,	similar	as	in	our	present	study,	which	focused	in	particular	on	functional	
outcomes.	
While	 functional	 recovery	did	compare	well	between	the	two	groups	 in	 the	present	study,	CD	patients,	who	were	
significantly	 younger	 than	 the	 comparative	 cancer	 group,	 experienced	 significantly	 more	 postoperative	 pain.	
Preoperative	chronic	pain	and	young	age	have	been	repeatedly	identified	as	risk	factors	for	increased	postoperative	
pain22,	23,	24,	25.	While	we	did	not	assess	preoperative	pain	intensity	in	the	setting	of	this	study,	both	subjective	(VAS	










younger	 patients	 as	 a	 result	 of	 decreased	 intra-operative	 IV	 fluid	 administration	 and	 increased	 post-operative	
mobilization	in	the	younger	CD	cohort.	 Indeed,	excessive	intraoperative	fluid	(>	2L)	 is	known	to	be	a	risk	factor	for	
delayed	postoperative	mobilization29.	Better	general	capacity	to	eliminate	excess	fluids	 in	younger	patients30	could	
























3.	 Mekhjian	 HS,	 Switz	 DM,	 Melnyk	 CS,	 Rankin	 GB,	 Brooks	 RK.	 Clinical	 features	 and	 natural	 history	 of	 Crohn’s	
disease.	Gastroenterology.	oct	1979;77(4):898‑906.		
4.		 Farmer	RG,	Whelan	G.	Long-Term	Follow-up	of	Patients	With	Crohn’s	Disease.	1985;88(6):8.		
5.	 Kang	WS,	Park	 YC,	 Jo	 YG,	Kim	 JC.	 Early	postoperative	 small	 bowel	obstruction	after	 laparotomy	 for	 trauma:	
incidence	and	risk	factors.	Ann	Surg	Treat	Res.	2018;94(2):94.	







9.		 de	 Barcelos	 IF,	 Kotze	 PG,	 Spinelli	 A,	 Suzuki	 Y,	 Teixeira	 FV,	 de	 Albuquerque	 IC,	 et	 al.	 Factors	 affecting	 the	
incidence	 of	 early	 endoscopic	 recurrence	 after	 ileocolonic	 resection	 for	 Crohn’s	 disease:	 a	 multicentre	
observational	study.	Colorectal	Dis.	janv	2017;19(1):O39‑45.		
10.		 Asada	 T,	 Nakayama	 G,	 Tanaka	 C,	 Kobayashi	 D,	 Ezaka	 K,	 Hattori	 N,	 et	 al.	 Postoperative	 adalimumab	
maintenance	 therapy	 for	 Japanese	 patients	 with	 Crohn’s	 disease:	 a	 single-center,	 single-arm	 phase	 II	 trial	
(CCOG-1107	study).	Surg	Today.	juin	2018;48(6):609‑17.		
11.		 Fortinsky	KJ,	Kevans	D,	Qiang	 J,	 Xu	W,	Bellolio	 F,	 Steinhart	H,	et	 al.	Rates	and	Predictors	of	Endoscopic	and	
Clinical	Recurrence	After	Primary	Ileocolic	Resection	for	Crohn’s	Disease.	Dig	Dis	Sci.	janv	2017;62(1):188‑96.		










15.		 Shivananda	 S,	 Hordijk	ML,	 Pena	 AS,	Mayberry	 JF.	 Crohn’s	 disease:	 risk	 of	 recurrence	 and	 reoperation	 in	 a	
defined	population.	Gut.	1	juill	1989;30(7):990‑5.		





18.		 Zulian	A,	Cancello	R,	Micheletto	G,	Gentilini	D,	Gilardini	 L,	Danelli	 P,	 et	 al.	Visceral	 adipocytes:	old	actors	 in	
obesity	and	new	protagonists	in	Crohn’s	disease?	Gut.	janv	2012;61(1):86‑94.		





right	 hemicolectomies	 for	 Crohn’s	 patients	 in	 comparison	 with	 non-Crohn’s	 patients	 and	 the	 impact	 of	
perioperative	 immunosuppressive	 therapy	 with	 biologics	 and	 steroids	 on	 inpatient	 complications.	 The	
American	Journal	of	Surgery.	mars	2012;203(3):375‑8.		
22.		 Cachemaille	M,	Grass	F,	Fournier	N,	Suter	MR,	Demartines	N,	Hübner	M,	et	al.	Pain	 Intensity	 in	 the	First	96	
Hours	After	Abdominal	Surgery:	A	Prospective	Cohort	Study.	Pain	Medicine.	19	juill	2019;pnz156.		
23.		 Gerbershagen	 HJ,	 Peelen	 LM,	 Kalkman	 CJ.	 Procedure-specific	 Risk	 Factor	 Analysis	 for	 the	 Development	 of	
Severe	Postoperative	Pain.	PAIN	MEDICINE.	:9.		
24.		 Gagliese	 L,	 Katz	 J.	Age	differences	 in	postoperative	pain	 are	 scale	dependent:	 a	 comparison	of	measures	of	
pain	intensity	and	quality	in	younger	and	older	surgical	patients:	Pain.	mai	2003;103(1):11‑20.		
25.	 Thomas	 T,	 Robinson	 C,	 Champion	 D,	McKell	M,	 Pell	M.	 Prediction	 and	 assessment	 of	 the	 severity	 of	 post-
operative	pain	and	of	satisfaction	with	management:	Pain.	janv	1998;75(2):177‑85.		
26.		 Bragg	 D,	 El-Sharkawy	 AM,	 Psaltis	 E,	 Maxwell-Armstrong	 CA,	 Lobo	 DN.	 Postoperative	 ileus:	 Recent	
developments	in	pathophysiology	and	management.	Clinical	Nutrition.	juin	2015;34(3):367‑76.		
27.	 Story	 SK,	 Chamberlain	 RS.	 A	 Comprehensive	 Review	 of	 Evidence-Based	 Strategies	 to	 Prevent	 and	 Treat	
Postoperative	Ileus.	Dig	Surg.	2009;26(4):265‑75.		




29.	 Grass	 F,	 Pache	 B,	 Martin	 D,	 Addor	 V,	 Hahnloser	 D,	 Demartines	 N,	 et	 al.	 Feasibility	 of	 early	 postoperative	
mobilisation	 after	 colorectal	 surgery:	 A	 retrospective	 cohort	 study.	 International	 Journal	 of	 Surgery.	 août	
2018;56:161‑6.		


























Age	(years;	mean±SD)	 64±20	 37±15	 71±14	 <0.001	
















BMI	(kg/m2;	mean±SD)	 25±6	 23±5	 26±6	 0.001	





































Emergency	indication	(%)	 49	(25)	 7	(17)	 42	(27)	 0.167	
Duration	of	operation	(min;	mean	±SD)	 150±70	 140±60	 150±70	 0.194	



































Preadmission	information	 165	(85)	 38	(90)	 127	(83)	 0.335	
















Thrombo-prophylaxis	 188	(96)	 42	(100)	 146	(95)	 0.350	










































Energy	(ONS)	at	POD	0	>300	kcal	 46/172	(27)	 13/36	(36)	 33/136	(24)	 0.203	
Total	oral	fluids	at	POD	0	>	800	mL	 84/165	(51)	 18/33	(55)	 66/132	(50)	 0.699	

















patients	 with	 adenocarcinoma	 (n=153)	 undergoing	 ileocecal	 resection	 or	 right	 colectomy.	 PONV	 –	 postoperative	




















































































































Functional	 outcome	 parameters	 of	 patients	 with	 Crohn’s	 disease	 (n=42)	 and	 patients	 with	 adenocarcinoma	




























































































































AZA	 –	 azathioprine,	 MTX	 –	 methotrexate,	 ADA	 –	 adalimumab,	 CTZ	 –	 certolizumab,	 IFX	 –	 infliximab,	 VED	 –	
vedolizumab,	UST-ustekinumab.	
	
Table	6:	Specifics	adenocarcinoma	patients	
Lymph	nodes	(n,	mean±SD)	
	Total		
								Positive		
		Peritumoral	
								Positive	peritumoral	
		Central	
								Positive	central	
	
26±13	
2±4	
14±9	
3±4	
12±9	
1±2	
Tumor	margins	(cm,	mean±SD)	
	Distal	(colonic)	
	Proximal	(ileal)	
	Vascular	pedicle	
	
10.2±5.6	
9.8±6.1	
7.5±4	
R0	resection	 152	(99)	
Pathologic	details	of	patients	with	adenocarcinoma	(n=153).	
